Gesellschaftsrecht / M&A

IP / IT

Kapitalmarkt

Steuern

Arbeitsrecht und Vergütung für Führungskräfte

Bioversys-web-640x140

Homburger News

20250129_Bioversys

On January 29, 2025, BioVersys AG, a clinical-stage biopharmaceutical company developing and commercializing novel antibacterial products for life-threatening infections domiciled in Basel, Switzerland, announced the launch of its Initial Public Offering (IPO) on SIX Swiss Exchange, the publication of the offer price and the start of the bookbuilding process. The IPO comprises a primary offering targeting gross proceeds of CHF 80 m (including an over-allotment option targeting gross proceeds of CHF 5 m). The implied market capitalization of the company, assuming all offered shares are sold in the IPO and the over-allotment option is exercised in full, is approximately CHF 212.9 m. The first day of trading is expected to be February 7, 2025.
BioVersys focuses on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The Company&#8217;s most advanced R&amp;D programs address nosocomial pneumonia and blood stream infections caused by Acinetobacter baumannii (BV100, phase 3-ready) and tuberculosis (alpibectir, phase 2a). In addition to its domicile in the biotech hub in Basel, Switzerland, BioVersys has operations in in Lille, France, Delaware, United States and Guangzhou, China.
Citigroup Global Markets Limited, UBS AG and Stifel Europe AG are acting as Joint Global Coordinators and Joint Bookrunners on the IPO, Mirabaud &amp; Cie SA and Octavian AG as Selling Agents.
Homburger is advising BioVersys on all aspects of the IPO as lead counsel. The Homburger team is co-led by Dieter Gericke and Lorenzo Togni and includes Thierry Burckhardt, Magda Aref, Simone Schmid, Raphael Linder, Harun Cetin and Leander Etter (all Corporate / M&amp;A and Capital Markets). Luca Dal Molin and Kristina Martinovic (both IP / IT) are providing intellectual property advice, Jeremy Reichlin (Employment and Executive Compensation) is providing employment and executive compensation advice, and Reto Heuberger and Philippe Weber (both Tax) are providing tax advice.

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Healthcare / Life Sciences

Noema Pharma

Homburger and Noema Pharma AG

On December 11, 2024, Noema Pharma AG announced that it has successfully closed a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 m (approx. USD 147 m). With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.
Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The new financing will support Noema Pharma&#8217;s four active Phase 2 trials, with key data readouts anticipated in 2025.
Homburger AG advised Noema Pharma AG as transaction counsel in this Series B extension financing round. The Homburger team comprised Andreas Müller, Thierry Burckhardt, Thomas Romelli and Rebecca Sigrist (all Corporate / M&amp;A; Healthcare / Life Sciences), Luca Dal Molin (IP / IT; Healthcare / Life Sciences) as well as Stefan Oesterhelt and Laetitia Fracheboud (Tax).

Homburger advised Noema Pharma AG on its Series B extension financing round

Share-Image Teamplate Deals-and-Cases

Homburger advised the Kellenberger family on the reduction of its shareholding in Calida Holding AG

The Kellenberger family has significantly reduced its shareholding in Calida Holding AG (the Company) in two transactions, a public buy-back offer and a direct repurchase.
Homburger advised the Kellenberger family on these transactions.
The Homburger team was led by Dieter Gericke and included Hansjürg Appenzeller, Daniel Häusermann, Cédric Berger, Thierry Burckhardt, Caspar Wehrle and Marc Abplanalp (all Corporate / M&amp;A) as well as Reto Heuberger, Arbnor Sheholli and Philipp Stiegeler (all Tax).

Thierry
Burckhardt

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Homburger advised Noema Pharma AG on its Series B extension financing round

Homburger advised the Kellenberger family on the reduction of its shareholding in Calida Holding AG

Private Equity 2024: Switzerland

Join the Team

Thierry Burckhardt

Karriere

Sprachen

Zulassung

Teams

ThierryBurckhardt

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Homburger advised Noema Pharma AG on its Series B extension financing round

Homburger advised the Kellenberger family on the reduction of its shareholding in Calida Holding AG

Private Equity 2024: Switzerland

Join the Team

Thierry Burckhardt

Karriere

Sprachen

Zulassung

Teams

Thierry
Burckhardt